🇺🇸 FDA

Intelligence · Clinical Pipeline

Infectious disease · Phase II

Infectious disease programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
375

Quick answer

Infectious disease Phase II programs: NovaPharmaNews indexes 375 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 3 of 8

  1. Cytovir-ADV

    United Therapeutics Europe Ltd

    ADV Infection Post Allo-HSCT

    phase 2 mab completed

    1 trial

  2. DAOIB

    Hospital Authority, Hong Kong

    Long COVID

    phase 2 small molecule active

    1 trial

  3. DASATINIB, Placebo

    The George Institute

    Asymptomatic patients with recent HIV-1 infection

    phase 2 small molecule active

    1 trial

  4. DNA vaccine prime

    United Therapeutics Europe Ltd

    Malaria

    phase 2 mab completed

    1 trial

  5. DOR/ISL

    Merck KGaA, Darmstadt, Germany

    HIV-1 Infection

    phase 2 small molecule completed

    1 trial

  6. DSM265

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule terminated

    2 trials

  7. Defibrotide

    Jazz Pharmaceuticals Ireland Limited

    Covid19

    phase 2 small molecule active

    1 trial

  8. Dexmedetomidine injection

    Sana Biotechnology

    Post Spinal Shivering

    phase 2 small molecule active

    1 trial

  9. Doravirine

    Merck KGaA, Darmstadt, Germany

    Human Immunodeficiency Virus (HIV) Infection

    phase 2 small molecule active

    1 trial

  10. Dovato 50 mg/300 mg film-coated tablets, Descovy 200 mg/25 mg film-coated tablets

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 2 small molecule active

    1 trial

  11. Doxycycline EG 200 mg Tabletten

    The George Institute

    Bacterial sexually transmittable diseases (chlamydia, gonorrhea, syphilis)

    phase 2 small molecule active

    1 trial

  12. Drug COVID19-0001-USR

    United Therapeutics Europe Ltd

    SARS-CoV-2 Infection

    phase 2 small molecule active

    1 trial

  13. Dupilumab

    CATALYST PHARMACEUTICALS, INC.

    COVID-19

    phase 2 mab completed

    1 trial

  14. Durability of protection after single immunisation with genetically attenuated Plasmodium falciparum ∆mei2 (GA2) sporozoites – a follow-up, controlled human malaria rechallenge study

    Disc Medicine

    Falciparum malaria

    phase 2 other active

    1 trial

  15. EDP-235

    ENANTA PHARMACEUTICALS INC

    COVID-19

    phase 2 small molecule completed

    3 trials

  16. EDP-305 1.5 mg

    ENANTA PHARMACEUTICALS INC

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule terminated

    1 trial

  17. EDP-305 Dose 1

    ENANTA PHARMACEUTICALS INC

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  18. EDP-323 Dose Regimen 1

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    1 trial

  19. EDP-938

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    6 trials

  20. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus Infections

    phase 2 small molecule terminated

    1 trial

  21. EDP-938 Dose 1

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    1 trial

  22. Encochleated Amphotericin B

    Matinas BioPharma Holdings

    Cryptococcal Infections

    phase 2 small molecule terminated

    1 trial

  23. Epetraborole

    AN2 Therapeutics

    Mycobacterium Abscessus Infection

    phase 2 small molecule active

    1 trial

  24. Evolution: Young Women Taking Charge and Growing Stronger

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  25. Extended-Release Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 small molecule completed

    1 trial

  26. FMP2.1/AS01B

    United Therapeutics Europe Ltd

    Plasmodium Falciparum Malaria

    phase 2 mab completed

    1 trial

  27. FSD201

    Quantum Biopharma

    COVID-19

    phase 2 small molecule terminated

    1 trial

  28. FST-100

    Takeda

    Acute Viral Conjunctivitis

    phase 2 small molecule completed

    1 trial

  29. FST-100

    Takeda

    Acute Adenoviral Conjunctivitis

    phase 2 small molecule completed

    1 trial

  30. FST-100 Ophthalmic Suspension

    Takeda

    Acute Adenoviral Conjunctivitis

    phase 2 small molecule terminated

    1 trial

  31. Ferroquine SSR97193

    Sanofi Pasteur

    Plasmodium Falciparum Infection

    phase 2 small molecule terminated

    1 trial

  32. Filgotinib

    Lakefront Biotherapeutics NV

    Noninfectious Uveitis

    phase 2 small molecule terminated

    1 trial

  33. Fludrocortisone 100 mcg daily

    Chinese University of Hong Kong

    Sepsis

    phase 2 small molecule active

    1 trial

  34. Full Spectrum Microbiota

    Finch Therapeutics Group

    Clostridium Difficile Infection Recurrence

    phase 2 small molecule completed

    1 trial

  35. GC4419

    Galera Therapeutics

    Covid19

    phase 2 small molecule terminated

    1 trial

  36. GLS4

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic HBV Infection

    phase 2 small molecule completed

    1 trial

  37. GLS4

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Hepatitis B

    phase 2 small molecule completed

    3 trials

  38. GR-MD-02

    GALECTIN THERAPEUTICS INC

    Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  39. GS-4321 PLACEBO

    Gilead Sciences Pty Limited

    Chronic Hepatitis Delta.

    phase 2 small molecule active

    1 trial

  40. GX-03

    Turn Therapeutics

    Covid19

    phase 2 small molecule completed

    1 trial

  41. Gamma-retroviral vector MP71 MC2 TCR16-3D9

    Disc Medicine

    advanced melanoma or HNSCC

    phase 2 small molecule active

    1 trial

  42. Gatifloxacin 0.3% ophthalmic solution

    Allergan Pharmaceuticals International Limited

    Acute Bacterial Corneal Ulcers

    phase 2 small molecule completed

    1 trial

  43. Gazyvaro 1,000 mg concentrate for solution for infusion.

    Pari Pharma GmbH

    Non-infectious active cryoglobulinemia vasculitis who are either refractory or intolerant to Rituximab

    phase 2 small molecule active

    1 trial

  44. Group A FMP2.1/AS01B

    United Therapeutics Europe Ltd

    Malaria

    phase 2 mab completed

    1 trial

  45. HB-adMSC

    United Therapeutics Europe Ltd

    COVID-19

    phase 2 mab terminated

    1 trial

  46. HEART to HAART

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  47. HEC110114 tablet

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Hepatitis C

    phase 2 small molecule completed

    2 trials

  48. HEC121120 tablets

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many infectious disease Phase II programs exist?

375 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.